The Visionary Future of CAR T-Cell Therapy
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.
Departments, Centers, & Programs:
Treats:
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 617-726-5130
Phone: 877-726-5130
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Mass General has two proton therapy centers and is the only hospital in New England to offer proton therapy on site.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2023-2024.
Noopur Raje, MD, Marcela Maus, MD, PhD and Matthew Frigault, MD discuss the power and evolution of immune therapies, specifically, CAR T-Cell therapy in treating cancer.
Billy Costa talks with Dr. Matt Frigault and oncology social worker Lauren DeMarco to learn more about the latest in CAR T-cell therapies and what it all means for patients.
It’s fitting that the investigators who developed a new CAR T-based treatment for glioblastoma called their treatment platform “CAR-TEAM” cells, as it took a true team effort to bring their concept from the lab to the clinic.
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
In this interview with Targeted Oncology, Matthew Frigault, MD discusses follow-up data on the efficacy and safety of CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma, particularly in later-line settings.